Shield Therapeutics (LSE:STX) announced plans to present pediatric pharmacokinetic data for ferric maltol at the upcoming American Society of Hematology (ASH) Conference. The findings demonstrate that ferric maltol is well-suited for iron replacement therapy in children, reinforcing its potential use in pediatric populations. The results support the company’s broader objective to expand access to effective and well-tolerated treatments for iron deficiency, addressing a key unmet medical need in pediatric care.
From a market perspective, Shield Therapeutics benefits from strong technical indicators that suggest positive trading momentum. However, persistent financial challenges — including negative profitability, limited cash flow, and a negative price-to-earnings ratio — continue to constrain valuation appeal. The absence of a dividend yield also tempers investor sentiment despite the company’s clinical progress.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company dedicated to developing and commercializing therapies for iron deficiency. Its lead product, ACCRUFeR®/FeRACCRU® (ferric maltol), is an oral treatment designed to provide effective iron supplementation with improved gastrointestinal tolerability. Shield operates primarily in the United States and maintains international partnerships across the UK, European Union, China, and Japan to expand the global reach of its iron deficiency treatment.









